drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00455 | DB01118 | 1,601 | 33 | [
"DDInter1091",
"DDInter76"
] | Loratadine | Amiodarone | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
1601,
24,
33
]
],
[
[
1601,
24,
540
],
[
540,
1,
33
]
],
[
[
1601,
6,
3486
],
[
3486,
45,
33
]
],
[
[
1601,
7,
7669
],
[
7669,
4... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Loratadine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Amiodarone (Compound)
Loratadine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) ... |
DB00242 | DB06043 | 1,064 | 1,644 | [
"DDInter392",
"DDInter1328"
] | Cladribine | Olaratumab | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Major | 2 | [
[
[
1064,
25,
1644
]
],
[
[
1064,
25,
1531
],
[
1531,
63,
1644
]
],
[
[
1064,
64,
1184
],
[
1184,
24,
1644
]
],
[
[
1064,
24,
1367
],
[
13... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaratumab"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u}... | Cladribine may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab
Cladribine may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate intera... |
DB00584 | DB01309 | 610 | 1,254 | [
"DDInter638",
"DDInter933"
] | Enalapril | Insulin glulisine | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
610,
24,
1254
]
],
[
[
610,
25,
1621
],
[
1621,
23,
1254
]
],
[
[
610,
25,
948
],
[
948,
62,
1254
]
],
[
[
610,
24,
167
],
[
167,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Enalapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
... | Enalapril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Enalapril may lead to a major life threatening interaction when taken with Potassium gluconate and Potassiu... |
DB00911 | DB09276 | 458 | 381 | [
"DDInter1811",
"DDInter1682"
] | Tinidazole | Sodium aurothiomalate | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Moderate | 1 | [
[
[
458,
24,
381
]
],
[
[
458,
63,
491
],
[
491,
24,
381
]
],
[
[
458,
24,
1047
],
[
1047,
24,
381
]
],
[
[
458,
40,
112
],
[
112,
2... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon al... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Tinidazole may cause a moderate interaction that could exacerbate diseases when... |
DB01059 | DB11348 | 956 | 1,065 | [
"DDInter1313",
"DDInter279"
] | Norfloxacin | Calcium Phosphate | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
956,
24,
1065
]
],
[
[
956,
40,
1299
],
[
1299,
24,
1065
]
],
[
[
956,
1,
872
],
[
872,
24,
1065
]
],
[
[
956,
40,
1299
],
[
1299,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Norfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may ... | Norfloxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Norfloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when tak... |
DB01177 | DB12015 | 77 | 1,033 | [
"DDInter904",
"DDInter53"
] | Idarubicin | Alpelisib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
77,
24,
1033
]
],
[
[
77,
64,
576
],
[
576,
24,
1033
]
],
[
[
77,
24,
738
],
[
738,
24,
1033
]
],
[
[
77,
25,
1510
],
[
1510,
24... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
... | Idarubicin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a mod... |
DB00163 | DB01030 | 1,461 | 869 | [
"DDInter1943",
"DDInter1835"
] | Vitamin E | Topotecan | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1461,
24,
869
]
],
[
[
1461,
24,
613
],
[
613,
24,
869
]
],
[
[
1461,
24,
310
],
[
310,
63,
869
]
],
[
[
1461,
62,
1184
],
[
1184,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazita... |
DB00218 | DB01309 | 1,176 | 1,254 | [
"DDInter1247",
"DDInter933"
] | Moxifloxacin | Insulin glulisine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Major | 2 | [
[
[
1176,
25,
1254
]
],
[
[
1176,
25,
1424
],
[
1424,
24,
1254
]
],
[
[
1176,
24,
1645
],
[
1645,
24,
1254
]
],
[
[
1176,
63,
305
],
[
305... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"... | Moxifloxacin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cau... |
DB00554 | DB12130 | 1,027 | 1,017 | [
"DDInter1478",
"DDInter1094"
] | Piroxicam | Lorlatinib | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1027,
24,
1017
]
],
[
[
1027,
63,
590
],
[
590,
24,
1017
]
],
[
[
1027,
24,
175
],
[
175,
24,
1017
]
],
[
[
1027,
25,
1421
],
[
1421,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and... |
DB00486 | DB00490 | 1,614 | 946 | [
"DDInter1253",
"DDInter254"
] | Nabilone | Buspirone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Moderate | 1 | [
[
[
1614,
24,
946
]
],
[
[
1614,
21,
29209
],
[
29209,
60,
946
]
],
[
[
1614,
63,
1242
],
[
1242,
24,
946
]
],
[
[
1614,
24,
1637
],
[
163... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {... | Nabilone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Buspirone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Nabi... |
DB08880 | DB11732 | 1,510 | 1,097 | [
"DDInter1771",
"DDInter1027"
] | Teriflunomide | Lasmiditan | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1510,
24,
1097
]
],
[
[
1510,
25,
971
],
[
971,
63,
1097
]
],
[
[
1510,
64,
77
],
[
77,
24,
1097
]
],
[
[
1510,
63,
1413
],
[
1413,
... | [
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gi... | Teriflunomide may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Teriflunomide may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a mod... |
DB00889 | DB06699 | 1,133 | 774 | [
"DDInter840",
"DDInter493"
] | Granisetron | Degarelix | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1133,
24,
774
]
],
[
[
1133,
63,
521
],
[
521,
1,
774
]
],
[
[
1133,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1133,
23,
112
],
[
112,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Granisetron (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Granisetron may cause a minor interaction that... |
DB01174 | DB01254 | 697 | 1,213 | [
"DDInter1442",
"DDInter484"
] | Phenobarbital | Dasatinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
697,
25,
1213
]
],
[
[
697,
6,
10509
],
[
10509,
45,
1213
]
],
[
[
697,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
697,
63,
112
],
[
112,... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1B1"
],
[
"CYP1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Da... | Phenobarbital (Compound) binds CYP1B1 (Gene) and CYP1B1 (Gene) is bound by Dasatinib (Compound)
Phenobarbital (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Phenobarbital may cause a moderate interaction that could exacerbate dis... |
DB09054 | DB15822 | 384 | 69 | [
"DDInter905",
"DDInter1504"
] | Idelalisib | Pralsetinib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Major | 2 | [
[
[
384,
25,
69
]
],
[
[
384,
25,
283
],
[
283,
24,
69
]
],
[
[
384,
64,
1213
],
[
1213,
24,
69
]
],
[
[
384,
63,
1648
],
[
1648,
24... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pralsetinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} ... | Idelalisib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Idelalisib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate inter... |
DB00877 | DB09098 | 629 | 98 | [
"DDInter1678",
"DDInter1700"
] | Sirolimus | Somatrem | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
629,
24,
98
]
],
[
[
629,
63,
608
],
[
608,
23,
98
]
],
[
[
629,
24,
671
],
[
671,
24,
98
]
],
[
[
629,
24,
159
],
[
159,
63,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin m... |
DB00393 | DB00877 | 854 | 629 | [
"DDInter1295",
"DDInter1678"
] | Nimodipine | Sirolimus | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
854,
24,
629
]
],
[
[
854,
6,
7524
],
[
7524,
45,
629
]
],
[
[
854,
7,
9489
],
[
9489,
46,
629
]
],
[
[
854,
21,
28921
],
[
28921,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Nimodipine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sirolimus (Compound)
Nimodipine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Sirolimus (Compound)
Nimodipine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sirolimus (Compound)
Nimodipine ... |
DB00980 | DB12015 | 969 | 1,033 | [
"DDInter1564",
"DDInter53"
] | Ramelteon | Alpelisib | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
969,
24,
1033
]
],
[
[
969,
63,
1144
],
[
1144,
24,
1033
]
],
[
[
969,
24,
1510
],
[
1510,
24,
1033
]
],
[
[
969,
24,
982
],
[
982,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teri... |
DB00586 | DB00710 | 1,512 | 1,199 | [
"DDInter537",
"DDInter897"
] | Diclofenac | Ibandronate | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Moderate | 1 | [
[
[
1512,
24,
1199
]
],
[
[
1512,
24,
1485
],
[
1485,
1,
1199
]
],
[
[
1512,
63,
963
],
[
963,
1,
1199
]
],
[
[
1512,
24,
1008
],
[
1008,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibandronate"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alendronic acid"
],
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Alendronic acid and Alendronic acid (Compound) resembles Ibandronate (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Zoledronic acid and Zoledronic acid (Compound) resembles I... |
DB01041 | DB09498 | 770 | 810 | [
"DDInter1789",
"DDInter1715"
] | Thalidomide | Strontium chloride Sr-89 | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
770,
24,
810
]
],
[
[
770,
64,
552
],
[
552,
24,
810
]
],
[
[
770,
63,
597
],
[
597,
24,
810
]
],
[
[
770,
25,
60
],
[
60,
24,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carmustine"
],
[
... | Thalidomide may lead to a major life threatening interaction when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and ... |
DB00063 | DB08901 | 366 | 1,468 | [
"DDInter659",
"DDInter1492"
] | Eptifibatide | Ponatinib | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
366,
25,
1468
]
],
[
[
366,
24,
1230
],
[
1230,
24,
1468
]
],
[
[
366,
24,
41
],
[
41,
63,
1468
]
],
[
[
366,
25,
4
],
[
4,
24,
... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalop... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran an... |
DB01037 | DB01142 | 1,161 | 1,264 | [
"DDInter1653",
"DDInter593"
] | Selegiline | Doxepin | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1161,
25,
1264
]
],
[
[
1161,
24,
401
],
[
401,
24,
1264
]
],
[
[
1161,
64,
1594
],
[
1594,
24,
1264
]
],
[
[
1161,
6,
4973
],
[
4973,... | [
[
[
"Selegiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazin... | Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Selegiline may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause... |
DB00619 | DB00661 | 1,419 | 122 | [
"DDInter909",
"DDInter1928"
] | Imatinib | Verapamil | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Moderate | 1 | [
[
[
1419,
24,
122
]
],
[
[
1419,
6,
12523
],
[
12523,
45,
122
]
],
[
[
1419,
21,
28809
],
[
28809,
60,
122
]
],
[
[
1419,
23,
222
],
[
222... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Verapamil (Compound)
Imatinib (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine m... |
DB00019 | DB00480 | 1,257 | 1,668 | [
"DDInter1405",
"DDInter1035"
] | Pegfilgrastim | Lenalidomide | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Moderate | 1 | [
[
[
1257,
24,
1668
]
],
[
[
1257,
24,
770
],
[
770,
40,
1668
]
],
[
[
1257,
24,
599
],
[
599,
24,
1668
]
],
[
[
1257,
24,
384
],
[
384,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interactio... |
DB00331 | DB01083 | 1,645 | 1,142 | [
"DDInter1164",
"DDInter1348"
] | Metformin | Orlistat | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
1645,
24,
1142
]
],
[
[
1645,
5,
11640
],
[
11640,
44,
1142
]
],
[
[
1645,
18,
5833
],
[
5833,
46,
1142
]
],
[
[
1645,
21,
28785
],
[
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Metformin",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u}... | Metformin (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Metformin (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Orlistat (Compound)
Metformin (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side E... |
DB00841 | DB09043 | 532 | 135 | [
"DDInter577",
"DDInter36"
] | Dobutamine | Albiglutide | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
532,
24,
135
]
],
[
[
532,
63,
1647
],
[
1647,
23,
135
]
],
[
[
532,
40,
1052
],
[
1052,
24,
135
]
],
[
[
532,
63,
176
],
[
176,
... | [
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Dobutamine (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacer... |
DB00014 | DB11057 | 521 | 720 | [
"DDInter839",
"DDInter1223"
] | Goserelin | Mineral oil | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
521,
24,
720
]
],
[
[
521,
24,
927
],
[
927,
63,
720
]
],
[
[
521,
24,
1151
],
[
1151,
24,
720
]
],
[
[
521,
25,
1069
],
[
1069,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suniti... |
DB09075 | DB11828 | 498 | 1,406 | [
"DDInter621",
"DDInter1281"
] | Edoxaban | Neratinib | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
498,
25,
1406
]
],
[
[
498,
64,
392
],
[
392,
24,
1406
]
],
[
[
498,
25,
1421
],
[
1421,
63,
1406
]
],
[
[
498,
24,
1456
],
[
1456,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may caus... | Edoxaban may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction... |
DB00960 | DB01268 | 887 | 1,151 | [
"DDInter1471",
"DDInter1731"
] | Pindolol | Sunitinib | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
887,
24,
1151
]
],
[
[
887,
18,
2602
],
[
2602,
45,
1151
]
],
[
[
887,
18,
3616
],
[
3616,
57,
1151
]
],
[
[
887,
21,
29269
],
[
29269... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Pindolol",
"{u} (Compound) downregulates {v} (Gene)",
"PTK2B"
],
[
"PTK2B",
"{u} (Gene) is bound by {v} (Compound)"... | Pindolol (Compound) downregulates PTK2B (Gene) and PTK2B (Gene) is bound by Sunitinib (Compound)
Pindolol (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Sunitinib (Compound)
Pindolol (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Suniti... |
DB00723 | DB06203 | 1,240 | 1,002 | [
"DDInter1176",
"DDInter51"
] | Methoxamine | Alogliptin | An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1240,
24,
1002
]
],
[
[
1240,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1240,
24,
1674
],
[
1674,
24,
1002
]
],
[
[
1240,
63,
176
],
[
176... | [
[
[
"Methoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Methoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[... | Methoxamine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Methoxamine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction ... |
DB06822 | DB14276 | 802 | 1,631 | [
"DDInter1812",
"DDInter1892"
] | Tinzaparin | Turmeric | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
802,
23,
1631
]
],
[
[
802,
64,
20
],
[
20,
23,
1631
]
],
[
[
802,
25,
1421
],
[
1421,
23,
1631
]
],
[
[
802,
64,
20
],
[
20,
24... | [
[
[
"Tinzaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase... | Tinzaparin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Tinzaparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a minor interac... |
DB00314 | DB11921 | 894 | 1,019 | [
"DDInter288",
"DDInter492"
] | Capreomycin | Deflazacort | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
894,
24,
1019
]
],
[
[
894,
25,
629
],
[
629,
24,
1019
]
],
[
[
894,
24,
123
],
[
123,
24,
1019
]
],
[
[
894,
24,
1220
],
[
1220,
... | [
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimu... | Capreomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a... |
DB00060 | DB00500 | 912 | 24 | [
"DDInter947",
"DDInter1831"
] | Interferon beta-1a | Tolmetin | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Moderate | 1 | [
[
[
912,
24,
24
]
],
[
[
912,
24,
886
],
[
886,
1,
24
]
],
[
[
912,
24,
1062
],
[
1062,
40,
24
]
],
[
[
912,
63,
1560
],
[
1560,
24,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Tolmetin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Tolmetin (Co... |
DB00879 | DB08880 | 1,279 | 1,510 | [
"DDInter637",
"DDInter1771"
] | Emtricitabine | Teriflunomide | Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse t... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1279,
25,
1510
]
],
[
[
1279,
23,
36
],
[
36,
25,
1510
]
],
[
[
1279,
24,
850
],
[
850,
25,
1510
]
],
[
[
1279,
1,
141
],
[
141,
... | [
[
[
"Emtricitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Emtricitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eribulin"
],
[
"Eribu... | Emtricitabine may cause a minor interaction that can limit clinical effects when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Emtricitabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuxim... |
DB01285 | DB06372 | 708 | 259 | [
"DDInter445",
"DDInter1594"
] | Corticotropin | Rilonacept | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
708,
24,
259
]
],
[
[
708,
24,
1367
],
[
1367,
63,
259
]
],
[
[
708,
63,
409
],
[
409,
24,
259
]
],
[
[
708,
24,
4
],
[
4,
24,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Corticotropin may cause a moderate interaction that could exace... |
DB00398 | DB00559 | 79 | 152 | [
"DDInter1702",
"DDInter223"
] | Sorafenib | Bosentan | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
79,
24,
152
]
],
[
[
79,
6,
6017
],
[
6017,
45,
152
]
],
[
[
79,
21,
29402
],
[
29402,
60,
152
]
],
[
[
79,
63,
1101
],
[
1101,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Sorafenib (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Bosentan (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Be... |
DB00569 | DB01105 | 553 | 222 | [
"DDInter775",
"DDInter1665"
] | Fondaparinux | Sibutramine | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
553,
24,
222
]
],
[
[
553,
21,
28698
],
[
28698,
60,
222
]
],
[
[
553,
25,
802
],
[
802,
63,
222
]
],
[
[
553,
64,
1027
],
[
1027,
... | [
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is c... | Fondaparinux (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound)
Fondaparinux may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Fondapa... |
DB00683 | DB11986 | 1,382 | 484 | [
"DDInter1212",
"DDInter648"
] | Midazolam | Entrectinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1382,
24,
484
]
],
[
[
1382,
24,
222
],
[
222,
23,
484
]
],
[
[
1382,
24,
1478
],
[
1478,
24,
484
]
],
[
[
1382,
24,
159
],
[
159,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacafto... |
DB01309 | DB04865 | 1,254 | 4 | [
"DDInter933",
"DDInter1335"
] | Insulin glulisine | Omacetaxine mepesuccinate | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1254,
24,
4
]
],
[
[
1254,
63,
485
],
[
485,
24,
4
]
],
[
[
1254,
24,
1616
],
[
1616,
63,
4
]
],
[
[
1254,
63,
914
],
[
914,
25,... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when t... |
DB08826 | DB15965 | 1,292 | 1,330 | [
"DDInter489",
"DDInter1270"
] | Deferiprone | Naxitamab | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Major | 2 | [
[
[
1292,
25,
1330
]
],
[
[
1292,
24,
1193
],
[
1193,
23,
1330
]
],
[
[
1292,
64,
1532
],
[
1532,
24,
1330
]
],
[
[
1292,
25,
350
],
[
350... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc ... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Deferiprone may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may... |
DB00620 | DB00790 | 175 | 664 | [
"DDInter1855",
"DDInter1431"
] | Triamcinolone | Perindopril | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Moderate | 1 | [
[
[
175,
24,
664
]
],
[
[
175,
63,
1638
],
[
1638,
1,
664
]
],
[
[
175,
24,
954
],
[
954,
40,
664
]
],
[
[
175,
24,
1058
],
[
1058,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (... |
DB08873 | DB11901 | 74 | 913 | [
"DDInter221",
"DDInter107"
] | Boceprevir | Apalutamide | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
74,
25,
913
]
],
[
[
74,
63,
608
],
[
608,
23,
913
]
],
[
[
74,
64,
303
],
[
303,
24,
913
]
],
[
[
74,
63,
609
],
[
609,
24,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine"... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Boceprevir may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxy... |
DB00424 | DB00652 | 19 | 234 | [
"DDInter896",
"DDInter1421"
] | Hyoscyamine | Pentazocine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
19,
24,
234
]
],
[
[
19,
24,
1359
],
[
1359,
40,
234
]
],
[
[
19,
21,
28762
],
[
28762,
60,
234
]
],
[
[
19,
24,
537
],
[
537,
6... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Hyoscyamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Pentazocine (Compound)
Hyoscyamine may cause a moderate interaction t... |
DB05812 | DB11110 | 1,374 | 603 | [
"DDInter8",
"DDInter1115"
] | Abiraterone | Magnesium citrate | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1374,
24,
603
]
],
[
[
1374,
64,
57
],
[
57,
24,
603
]
],
[
[
1374,
63,
789
],
[
789,
24,
603
]
],
[
[
1374,
24,
484
],
[
484,
6... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Abiraterone may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and F... |
DB00502 | DB00792 | 1,300 | 832 | [
"DDInter853",
"DDInter1878"
] | Haloperidol | Tripelennamine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1300,
24,
832
]
],
[
[
1300,
24,
100
],
[
100,
63,
832
]
],
[
[
1300,
25,
1264
],
[
1264,
63,
832
]
],
[
[
1300,
24,
649
],
[
649,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Haloperidol may lead to a major life threatening interaction when taken with Doxepin and Doxepin ... |
DB00889 | DB01165 | 1,133 | 1,539 | [
"DDInter840",
"DDInter1325"
] | Granisetron | Ofloxacin | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
1133,
24,
1539
]
],
[
[
1133,
64,
1176
],
[
1176,
1,
1539
]
],
[
[
1133,
25,
945
],
[
945,
40,
1539
]
],
[
[
1133,
24,
956
],
[
956,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxiflo... | Granisetron may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Granisetron may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Granisetron may cause ... |
DB01115 | DB06168 | 336 | 1,531 | [
"DDInter1291",
"DDInter281"
] | Nifedipine | Canakinumab | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
336,
24,
1531
]
],
[
[
336,
24,
1362
],
[
1362,
63,
1531
]
],
[
[
336,
24,
1213
],
[
1213,
24,
1531
]
],
[
[
336,
62,
1031
],
[
1031,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib ... |
DB01191 | DB06603 | 1,039 | 39 | [
"DDInter518",
"DDInter1387"
] | Dexfenfluramine | Panobinostat | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1039,
25,
39
]
],
[
[
1039,
62,
479
],
[
479,
23,
39
]
],
[
[
1039,
64,
506
],
[
506,
24,
39
]
],
[
[
1039,
24,
578
],
[
578,
63... | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"D... | Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Dexfenfluramine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromet... |
DB00701 | DB01132 | 1,091 | 1,130 | [
"DDInter90",
"DDInter1472"
] | Amprenavir | Pioglitazone | Amprenavir is a protease inhibitor used to treat HIV infection. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1091,
24,
1130
]
],
[
[
1091,
6,
12523
],
[
12523,
45,
1130
]
],
[
[
1091,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
1091,
64,
303
],
[
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Amprenavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Amprenavir (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Amprenavir may lead to a major life threatening interaction when taken with Me... |
DB00640 | DB01069 | 1,585 | 401 | [
"DDInter31",
"DDInter1533"
] | Adenosine | Promethazine | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1585,
24,
401
]
],
[
[
1585,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1585,
21,
29169
],
[
29169,
60,
401
]
],
[
[
1585,
24,
1559
],
[
155... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Adenosine (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Promethazine (Compound)
Ad... |
DB00661 | DB11793 | 122 | 738 | [
"DDInter1928",
"DDInter1297"
] | Verapamil | Niraparib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
122,
24,
738
]
],
[
[
122,
23,
466
],
[
466,
63,
738
]
],
[
[
122,
24,
1213
],
[
1213,
24,
738
]
],
[
[
122,
24,
1033
],
[
1033,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Verapamil may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatini... |
DB00342 | DB00619 | 1,181 | 1,419 | [
"DDInter1770",
"DDInter909"
] | Terfenadine | Imatinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
1181,
24,
1419
]
],
[
[
1181,
24,
479
],
[
479,
62,
1419
]
],
[
[
1181,
64,
1230
],
[
1230,
23,
1419
]
],
[
[
1181,
25,
318
],
[
318,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Imatinib
Terfenadine may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a mi... |
DB01232 | DB06788 | 1,327 | 1,616 | [
"DDInter1640",
"DDInter864"
] | Saquinavir | Histrelin | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
1327,
25,
1616
]
],
[
[
1327,
62,
112
],
[
112,
23,
1616
]
],
[
[
1327,
25,
1342
],
[
1342,
24,
1616
]
],
[
[
1327,
24,
170
],
[
170,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Saquinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Saquinavir may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause... |
DB00783 | DB09564 | 1,438 | 1,296 | [
"DDInter679",
"DDInter930"
] | Estradiol | Insulin degludec | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1438,
24,
1296
]
],
[
[
1438,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1438,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1438,
1,
380
],
[
380,... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Metformin and M... |
DB00531 | DB14550 | 450 | 821 | [
"DDInter456",
"DDInter803"
] | Cyclophosphamide | Gallium chloride Ga-67 | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Gallium chloride Ga-67 is the chloride salt of a gallium radioisotope which is typically complexed with [sodium citrate] to generate [gallium citrate Ga 67], which can be used to image certain cancers and inflammatory lesions. | Moderate | 1 | [
[
[
450,
24,
821
]
],
[
[
450,
1,
1001
],
[
1001,
24,
821
]
],
[
[
450,
24,
1224
],
[
1224,
24,
821
]
],
[
[
450,
1,
1001
],
[
1001,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium chloride Ga-67"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) resembles {v} (Compound)",
"Mechlorethamine"
],
[
"Mechlorethamin... | Cyclophosphamide (Compound) resembles Mechlorethamine (Compound) and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine may cause... |
DB00552 | DB08826 | 1,238 | 1,292 | [
"DDInter1425",
"DDInter489"
] | Pentostatin | Deferiprone | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1238,
25,
1292
]
],
[
[
1238,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
1238,
40,
1426
],
[
1426,
25,
1292
]
],
[
[
1238,
24,
1419
],
[
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Pentostatin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (C... | Pentostatin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Pentostatin (Compound) resembles Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Deferiprone
Pentostatin may cause a moderate interaction that cou... |
DB00618 | DB11348 | 1,572 | 1,065 | [
"DDInter498",
"DDInter279"
] | Demeclocycline | Calcium Phosphate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1572,
24,
1065
]
],
[
[
1572,
62,
1014
],
[
1014,
24,
1065
]
],
[
[
1572,
40,
1620
],
[
1620,
24,
1065
]
],
[
[
1572,
23,
359
],
[
359... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
... | Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Demeclocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate i... |
DB00397 | DB06707 | 1,466 | 584 | [
"DDInter1458",
"DDInter1060"
] | Phenylpropanolamine | Levonordefrin | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
1466,
35,
584
]
],
[
[
1466,
24,
1191
],
[
1191,
40,
584
]
],
[
[
1466,
24,
1354
],
[
1354,
1,
584
]
],
[
[
1466,
24,
1148
],
[
1148,
... | [
[
[
"Phenylpropanolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate ... | Phenylpropanolamine (Compound) resembles Levonordefrin (Compound) and
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Levonordefrin (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate disease... |
DB00065 | DB00307 | 581 | 1,101 | [
"DDInter923",
"DDInter202"
] | Infliximab | Bexarotene | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Major | 2 | [
[
[
581,
25,
1101
]
],
[
[
581,
24,
608
],
[
608,
23,
1101
]
],
[
[
581,
24,
597
],
[
597,
62,
1101
]
],
[
[
581,
25,
1419
],
[
1419,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chlor... |
DB00834 | DB01069 | 932 | 401 | [
"DDInter1215",
"DDInter1533"
] | Mifepristone | Promethazine | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Major | 2 | [
[
[
932,
25,
401
]
],
[
[
932,
25,
1264
],
[
1264,
63,
401
]
],
[
[
932,
6,
12523
],
[
12523,
45,
401
]
],
[
[
932,
21,
28709
],
[
28709,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} m... | Mifepristone may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Mifepristone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Promethazine (Compound)
Mifepristone (Compound) causes ... |
DB11718 | DB15982 | 927 | 1,339 | [
"DDInter640",
"DDInter193"
] | Encorafenib | Berotralstat | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
927,
25,
1339
]
],
[
[
927,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
927,
25,
283
],
[
283,
23,
1339
]
],
[
[
927,
63,
761
],
[
761,
... | [
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Encorafenib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may caus... |
DB00526 | DB08864 | 1,555 | 786 | [
"DDInter1355",
"DDInter1595"
] | Oxaliplatin | Rilpivirine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
1555,
24,
786
]
],
[
[
1555,
24,
655
],
[
655,
1,
786
]
],
[
[
1555,
6,
17404
],
[
17404,
45,
786
]
],
[
[
1555,
24,
112
],
[
112,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Oxaliplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Rilpivirine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerba... |
DB08908 | DB11730 | 713 | 351 | [
"DDInter564",
"DDInter1588"
] | Dimethyl fumarate | Ribociclib | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
713,
24,
351
]
],
[
[
713,
24,
1627
],
[
1627,
23,
351
]
],
[
[
713,
63,
310
],
[
310,
24,
351
]
],
[
[
713,
24,
987
],
[
987,
6... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Cabazit... |
DB00014 | DB00731 | 521 | 1,144 | [
"DDInter839",
"DDInter1269"
] | Goserelin | Nateglinide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
521,
24,
1144
]
],
[
[
521,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
521,
24,
1005
],
[
1005,
63,
1144
]
],
[
[
521,
25,
17
],
[
17,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is cau... | Goserelin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Nategl... |
DB00900 | DB05773 | 45 | 1,047 | [
"DDInter544",
"DDInter1848"
] | Didanosine | Trastuzumab emtansine | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
45,
24,
1047
]
],
[
[
45,
24,
375
],
[
375,
63,
1047
]
],
[
[
45,
24,
458
],
[
458,
24,
1047
]
],
[
[
45,
63,
467
],
[
467,
24,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab peg... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Didanosine may cause a moderate interaction that could exacerbate diseases when taken... |
DB09146 | DB12455 | 489 | 933 | [
"DDInter978",
"DDInter1336"
] | Iron sucrose | Omadacycline | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Moderate | 1 | [
[
[
489,
24,
933
]
],
[
[
489,
24,
428
],
[
428,
63,
933
]
],
[
[
489,
63,
1596
],
[
1596,
24,
933
]
],
[
[
489,
24,
428
],
[
428,
6... | [
[
[
"Iron sucrose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron sucrose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
... | Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with Iro... |
DB09330 | DB14444 | 985 | 151 | [
"DDInter1352",
"DDInter924"
] | Osimertinib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
985,
24,
151
]
],
[
[
985,
63,
66
],
[
66,
24,
151
]
],
[
[
985,
25,
1619
],
[
1619,
24,
151
]
],
[
[
985,
64,
36
],
[
36,
24,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Osimertinib may lead to a major life... |
DB00445 | DB11363 | 322 | 1,276 | [
"DDInter655",
"DDInter39"
] | Epirubicin | Alectinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
322,
24,
1276
]
],
[
[
322,
63,
305
],
[
305,
24,
1276
]
],
[
[
322,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
322,
24,
850
],
[
850,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia col... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Epirubicin may lead to a major life threatening interaction when taken with... |
DB00250 | DB00673 | 10 | 723 | [
"DDInter475",
"DDInter112"
] | Dapsone | Aprepitant | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
10,
24,
723
]
],
[
[
10,
24,
875
],
[
875,
40,
723
]
],
[
[
10,
6,
6799
],
[
6799,
45,
723
]
],
[
[
10,
21,
28698
],
[
28698,
60... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Dapsone (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Aprepitant (Compound)
Dapsone (Compound) causes Insomnia (Side Effect) and Insomnia (Sid... |
DB00065 | DB08870 | 581 | 850 | [
"DDInter923",
"DDInter228"
] | Infliximab | Brentuximab vedotin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Major | 2 | [
[
[
581,
25,
850
]
],
[
[
581,
24,
788
],
[
788,
24,
850
]
],
[
[
581,
24,
496
],
[
496,
63,
850
]
],
[
[
581,
25,
611
],
[
611,
24,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Hepatiti... |
DB00087 | DB01285 | 599 | 708 | [
"DDInter41",
"DDInter445"
] | Alemtuzumab | Corticotropin | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
599,
24,
708
]
],
[
[
599,
24,
1136
],
[
1136,
63,
708
]
],
[
[
599,
63,
1184
],
[
1184,
24,
708
]
],
[
[
599,
24,
589
],
[
589,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anaki... |
DB00046 | DB14730 | 1,179 | 1,412 | [
"DDInter940",
"DDInter264"
] | Insulin lispro | Calaspargase pegol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1179,
24,
1412
]
],
[
[
1179,
24,
5
],
[
5,
24,
1412
]
],
[
[
1179,
24,
1101
],
[
1101,
25,
1412
]
],
[
[
1179,
24,
5
],
[
5,
63... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bex... |
DB00201 | DB14509 | 1,684 | 1,399 | [
"DDInter263",
"DDInter1081"
] | Caffeine | Lithium carbonate | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1684,
24,
1399
]
],
[
[
1684,
23,
1479
],
[
1479,
23,
1399
]
],
[
[
1684,
24,
1031
],
[
1031,
24,
1399
]
],
[
[
1684,
24,
985
],
[
985... | [
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
... | Caffeine may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Th... |
DB00726 | DB00757 | 1,164 | 1,166 | [
"DDInter1876",
"DDInter581"
] | Trimipramine | Dolasetron | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
1164,
25,
1166
]
],
[
[
1164,
63,
19
],
[
19,
40,
1166
]
],
[
[
1164,
63,
85
],
[
85,
1,
1166
]
],
[
[
1164,
6,
12523
],
[
12523,
... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyosc... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound... |
DB00495 | DB01083 | 139 | 1,142 | [
"DDInter1961",
"DDInter1348"
] | Zidovudine | Orlistat | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
139,
24,
1142
]
],
[
[
139,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
139,
21,
28645
],
[
28645,
60,
1142
]
],
[
[
139,
1,
1477
],
[
1477,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Zidovudine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Orlistat (Compound)
Zidovudine (Compound) resembles Telbivudine (Compound) and Telbivudine may cause a moderate interaction that could exacerb... |
DB06203 | DB12015 | 1,002 | 1,033 | [
"DDInter51",
"DDInter53"
] | Alogliptin | Alpelisib | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1002,
24,
1033
]
],
[
[
1002,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
1002,
24,
154
],
[
154,
24,
1033
]
],
[
[
1002,
64,
1101
],
[
1101... | [
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Lurasido... |
DB00586 | DB01138 | 1,512 | 804 | [
"DDInter537",
"DDInter1726"
] | Diclofenac | Sulfinpyrazone | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
1512,
24,
804
]
],
[
[
1512,
24,
998
],
[
998,
1,
804
]
],
[
[
1512,
6,
3486
],
[
3486,
45,
804
]
],
[
[
1512,
24,
1144
],
[
1144,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Diclofenac (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfinpyrazone (Compound)
Diclofenac may cause a moderate interaction that c... |
DB00019 | DB15699 | 1,257 | 652 | [
"DDInter1405",
"DDInter232"
] | Pegfilgrastim | Brexucabtagene autoleucel | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Moderate | 1 | [
[
[
1257,
24,
652
]
],
[
[
1257,
24,
4
],
[
4,
24,
652
]
],
[
[
1257,
25,
1064
],
[
1064,
25,
652
]
],
[
[
1257,
24,
4
],
[
4,
24,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacet... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Pegfilgrastim may lead to a major life threatening interaction w... |
DB00388 | DB00816 | 1,636 | 1,674 | [
"DDInter1453",
"DDInter1346"
] | Phenylephrine | Orciprenaline | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
1636,
24,
1674
]
],
[
[
1636,
1,
874
],
[
874,
24,
1674
]
],
[
[
1636,
40,
454
],
[
454,
1,
1674
]
],
[
[
1636,
21,
28921
],
[
28921,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may caus... | Phenylephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Phenylephrine (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Orciprenaline (Compound)
Phenylephrine (Compound) causes ... |
DB01105 | DB11952 | 222 | 800 | [
"DDInter1665",
"DDInter612"
] | Sibutramine | Duvelisib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Minor | 0 | [
[
[
222,
23,
800
]
],
[
[
222,
62,
522
],
[
522,
24,
800
]
],
[
[
222,
63,
1324
],
[
1324,
24,
800
]
],
[
[
222,
24,
1213
],
[
1213,
... | [
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Duvelisib"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
],
[
... | Sibutramine may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tro... |
DB00782 | DB00915 | 1,123 | 1,170 | [
"DDInter1535",
"DDInter60"
] | Propantheline | Amantadine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesi... | Moderate | 1 | [
[
[
1123,
24,
1170
]
],
[
[
1123,
21,
29083
],
[
29083,
60,
1170
]
],
[
[
1123,
63,
1219
],
[
1219,
24,
1170
]
],
[
[
1123,
24,
832
],
[
8... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amantadine"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Mydriasis"
],
[
"Mydriasis",
"{u} (Side Effect) i... | Propantheline (Compound) causes Mydriasis (Side Effect) and Mydriasis (Side Effect) is caused by Amantadine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Ama... |
DB00186 | DB01156 | 905 | 593 | [
"DDInter1092",
"DDInter252"
] | Lorazepam | Bupropion | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
905,
24,
593
]
],
[
[
905,
10,
11621
],
[
11621,
49,
593
]
],
[
[
905,
21,
29094
],
[
29094,
60,
593
]
],
[
[
905,
24,
1532
],
[
1532,... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Lorazepam",
"{u} (Compound) palliates {v} (Disease)",
"panic disorder"
],
[
"panic disorder",
"{u} (Disease) is pa... | Lorazepam (Compound) palliates panic disorder (Disease) and panic disorder (Disease) is palliated by Bupropion (Compound)
Lorazepam (Compound) causes Thinking abnormal (Side Effect) and Thinking abnormal (Side Effect) is caused by Bupropion (Compound)
Lorazepam may cause a moderate interaction that could exacerbate dis... |
DB00188 | DB04865 | 168 | 4 | [
"DDInter222",
"DDInter1335"
] | Bortezomib | Omacetaxine mepesuccinate | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
168,
24,
4
]
],
[
[
168,
18,
13042
],
[
13042,
46,
4
]
],
[
[
168,
7,
7689
],
[
7689,
46,
4
]
],
[
[
168,
6,
9842
],
[
9842,
46,... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"HIST1H2BK"
],
[
"HIST1H2BK",
"{u} (Gene)... | Bortezomib (Compound) downregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Bortezomib (Compound) upregulates TXNL4B (Gene) and TXNL4B (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Bortezomib (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregul... |
DB06616 | DB12035 | 594 | 943 | [
"DDInter224",
"DDInter1641"
] | Bosutinib | Sarecycline | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
594,
24,
943
]
],
[
[
594,
63,
1181
],
[
1181,
24,
943
]
],
[
[
594,
24,
1456
],
[
1456,
24,
943
]
],
[
[
594,
24,
1619
],
[
1619,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venet... |
DB00443 | DB06688 | 251 | 1,430 | [
"DDInter195",
"DDInter1677"
] | Betamethasone | Sipuleucel-T | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
251,
24,
1430
]
],
[
[
251,
1,
175
],
[
175,
24,
1430
]
],
[
[
251,
25,
676
],
[
676,
63,
1430
]
],
[
[
251,
24,
1531
],
[
1531,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may c... | Betamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that co... |
DB01105 | DB01124 | 222 | 1,411 | [
"DDInter1665",
"DDInter1828"
] | Sibutramine | Tolbutamide | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
222,
24,
1411
]
],
[
[
222,
63,
959
],
[
959,
40,
1411
]
],
[
[
222,
21,
29222
],
[
29222,
60,
1411
]
],
[
[
222,
63,
1347
],
[
1347,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Sibutramine (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Tolbutamide (Compound)
Sibutramine may cause a moderate i... |
DB00398 | DB06699 | 79 | 774 | [
"DDInter1702",
"DDInter493"
] | Sorafenib | Degarelix | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
79,
24,
774
]
],
[
[
79,
63,
521
],
[
521,
1,
774
]
],
[
[
79,
21,
29232
],
[
29232,
60,
774
]
],
[
[
79,
23,
112
],
[
112,
23,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Sorafenib (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Sorafenib may cause a minor interaction that can l... |
DB00448 | DB06817 | 1,215 | 809 | [
"DDInter1022",
"DDInter1563"
] | Lansoprazole | Raltegravir | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Minor | 0 | [
[
[
1215,
23,
809
]
],
[
[
1215,
21,
29122
],
[
29122,
60,
809
]
],
[
[
1215,
40,
379
],
[
379,
23,
809
]
],
[
[
1215,
24,
478
],
[
478,
... | [
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
]
],
[
[
"Lansoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"... | Lansoprazole (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Raltegravir (Compound)
Lansoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Lansoprazole may... |
DB00845 | DB06595 | 1,490 | 1,491 | [
"DDInter406",
"DDInter1214"
] | Clofazimine | Midostaurin | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1490,
24,
1491
]
],
[
[
1490,
23,
112
],
[
112,
23,
1491
]
],
[
[
1490,
63,
888
],
[
888,
24,
1491
]
],
[
[
1490,
24,
657
],
[
657,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Ta... |
DB00488 | DB00780 | 196 | 551 | [
"DDInter57",
"DDInter1440"
] | Altretamine | Phenelzine | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
196,
24,
551
]
],
[
[
196,
21,
28722
],
[
28722,
60,
551
]
],
[
[
196,
25,
770
],
[
770,
63,
551
]
],
[
[
196,
24,
1264
],
[
1264,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused b... | Altretamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Phenelzine (Compound)
Altretamine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine
Altretamine m... |
DB00006 | DB12364 | 942 | 1,421 | [
"DDInter217",
"DDInter200"
] | Bivalirudin | Betrixaban | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
942,
25,
1421
]
],
[
[
942,
23,
297
],
[
297,
23,
1421
]
],
[
[
942,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
942,
24,
992
],
[
992,
... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a m... |
DB00312 | DB01075 | 1,023 | 1,376 | [
"DDInter1423",
"DDInter569"
] | Pentobarbital | Diphenhydramine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
1023,
24,
1376
]
],
[
[
1023,
24,
649
],
[
649,
63,
1376
]
],
[
[
1023,
24,
11
],
[
11,
1,
1376
]
],
[
[
1023,
24,
128
],
[
128,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Toremifene... |
DB00014 | DB00261 | 521 | 702 | [
"DDInter839",
"DDInter93"
] | Goserelin | Anagrelide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Major | 2 | [
[
[
521,
25,
702
]
],
[
[
521,
21,
29549
],
[
29549,
60,
702
]
],
[
[
521,
23,
112
],
[
112,
62,
702
]
],
[
[
521,
24,
62
],
[
62,
6... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Osteoarthritis"
],
[
"Osteoarthritis",
"{u} (Side Effect) is caused by {... | Goserelin (Compound) causes Osteoarthritis (Side Effect) and Osteoarthritis (Side Effect) is caused by Anagrelide (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken wi... |
DB01114 | DB11859 | 272 | 418 | [
"DDInter362",
"DDInter230"
] | Chlorpheniramine | Brexanolone | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
272,
24,
418
]
],
[
[
272,
24,
820
],
[
820,
24,
418
]
],
[
[
272,
74,
100
],
[
100,
24,
418
]
],
[
[
272,
63,
104
],
[
104,
24,... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moder... |
DB00242 | DB00564 | 1,064 | 1,236 | [
"DDInter392",
"DDInter293"
] | Cladribine | Carbamazepine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Major | 2 | [
[
[
1064,
25,
1236
]
],
[
[
1064,
24,
362
],
[
362,
1,
1236
]
],
[
[
1064,
7,
2789
],
[
2789,
46,
1236
]
],
[
[
1064,
5,
11594
],
[
11594,... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoi... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Cladribine (Compound) upregulates PLCB3 (Gene) and PLCB3 (Gene) is upregulated by Carbamazepine (Compound)
Cladribine (Compound) treats multiple sclerosis (Dis... |
DB09098 | DB12457 | 98 | 1,180 | [
"DDInter1700",
"DDInter1598"
] | Somatrem | Rimegepant | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
98,
24,
1180
]
],
[
[
98,
24,
741
],
[
741,
24,
1180
]
],
[
[
98,
63,
1419
],
[
1419,
24,
1180
]
],
[
[
98,
24,
283
],
[
283,
63... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may... |
DB00346 | DB08899 | 472 | 129 | [
"DDInter44",
"DDInter649"
] | Alfuzosin | Enzalutamide | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
472,
24,
129
]
],
[
[
472,
24,
918
],
[
918,
1,
129
]
],
[
[
472,
6,
8374
],
[
8374,
45,
129
]
],
[
[
472,
21,
28703
],
[
28703,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Alfuzosin (Compound) causes Pruritus (Side Effect) and Pruri... |
DB00717 | DB01309 | 1,197 | 1,254 | [
"DDInter1312",
"DDInter933"
] | Norethisterone | Insulin glulisine | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1197,
24,
1254
]
],
[
[
1197,
40,
167
],
[
167,
24,
1254
]
],
[
[
1197,
24,
1094
],
[
1094,
63,
1254
]
],
[
[
1197,
63,
1645
],
[
1645... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"... | Norethisterone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a modera... |
DB00072 | DB01004 | 550 | 563 | [
"DDInter1846",
"DDInter806"
] | Trastuzumab | Ganciclovir | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
550,
24,
563
]
],
[
[
550,
24,
248
],
[
248,
40,
563
]
],
[
[
550,
25,
770
],
[
770,
63,
563
]
],
[
[
550,
24,
869
],
[
869,
63,... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could e... |
DB00515 | DB09115 | 589 | 505 | [
"DDInter387",
"DDInter559"
] | Cisplatin | Diiodohydroxyquinoline | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
589,
24,
505
]
],
[
[
589,
24,
1593
],
[
1593,
24,
505
]
],
[
[
589,
25,
908
],
[
908,
24,
505
]
],
[
[
589,
63,
168
],
[
168,
2... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Cisplatin may lead to a major life threatening interaction when taken with Golimumab and Golimumab ma... |
DB00641 | DB11718 | 467 | 927 | [
"DDInter1675",
"DDInter640"
] | Simvastatin | Encorafenib | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
467,
24,
927
]
],
[
[
467,
24,
112
],
[
112,
23,
927
]
],
[
[
467,
63,
372
],
[
372,
24,
927
]
],
[
[
467,
24,
1491
],
[
1491,
2... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine an... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.